PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-222-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$264.73 million
Profitability
Miscellaneous
Employees511
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable
PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions
What is PTC Therapeutics' stock symbol?
PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."
How were PTC Therapeutics' earnings last quarter?
PTC Therapeutics, Inc. (NASDAQ:PTCT) released its quarterly earnings data on Tuesday, August, 6th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.20. The biopharmaceutical company had revenue of $85.50 million for the quarter, compared to analysts' expectations of $78.65 million. PTC Therapeutics had a negative return on equity of 35.79% and a negative net margin of 76.41%. PTC Therapeutics's revenue for the quarter was up 24.5% on a year-over-year basis. During the same period last year, the firm posted ($0.21) earnings per share. View PTC Therapeutics' Earnings History.
When is PTC Therapeutics' next earnings date?
How can I listen to PTC Therapeutics' earnings call?
PTC Therapeutics will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for PTCT?
9 Wall Street analysts have issued 12-month target prices for PTC Therapeutics' stock. Their forecasts range from $43.00 to $62.00. On average, they expect PTC Therapeutics' share price to reach $51.43 in the next year. This suggests a possible upside of 41.8% from the stock's current price. View Analyst Price Targets for PTC Therapeutics.
What is the consensus analysts' recommendation for PTC Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PTC Therapeutics.
What are Wall Street analysts saying about PTC Therapeutics stock?
Here are some recent quotes from research analysts about PTC Therapeutics stock:
- 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (10/18/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $61 Price Target and think that risk/reward is positive for PTC heading into updates on SMA and AADC. After today’s update, we remain confident in both the regulatory and commercial pathway for risdiplam and view it as a largely underappreciated opportunity for PTC. The company is eligible to receive $15M in milestone payments each for NDA and MAA filings and $20M each for first US and EU sale. We model $3B 2025 WW sales for risdiplam and $360M 2025 royalties to PTC on an unadjusted basis. We expect further updates on these data at AAN (May 4-10)." (2/28/2019)
Has PTC Therapeutics been receiving favorable news coverage?
News headlines about PTCT stock have been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PTC Therapeutics earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for PTC Therapeutics.
Who are some of PTC Therapeutics' key competitors?
Some companies that are related to PTC Therapeutics include GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Beigene (BGNE), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP) and Reata Pharmaceuticals (RETA).
What other stocks do shareholders of PTC Therapeutics own?
Who are PTC Therapeutics' key executives?
PTC Therapeutics' management team includes the folowing people:
- Dr. Stuart W. Peltz, Co-Founder, CEO & Exec. Director (Age 59)
- Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 73)
- Ms. Christine Utter, Principal Financial Officer & Treasurer (Age 41)
- Mr. Marcio Souza, Chief Operating Officer (Age 40)
- Dr. Neil Almstead, Chief Technical Operations Officer (Age 52)
Who are PTC Therapeutics' major shareholders?
PTC Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Nadler Financial Group Inc. (0.01%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Meeder Asset Management Inc. (0.00%). Company insiders that own PTC Therapeutics stock include Christine Marie Utter, Marcio Souza, Mark Elliott Boulding, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz. View Institutional Ownership Trends for PTC Therapeutics.
Which major investors are buying PTC Therapeutics stock?
How do I buy shares of PTC Therapeutics?
Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is PTC Therapeutics' stock price today?
One share of PTCT stock can currently be purchased for approximately $36.28.
How big of a company is PTC Therapeutics?
PTC Therapeutics has a market capitalization of $2.23 billion and generates $264.73 million in revenue each year. The biopharmaceutical company earns $-128,080,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. PTC Therapeutics employs 511 workers across the globe.View Additional Information About PTC Therapeutics.
What is PTC Therapeutics' official website?
How can I contact PTC Therapeutics?
PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]
MarketBeat Community Rating for PTC Therapeutics (NASDAQ PTCT)
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe PTCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
